CGEM 8-K 2026-11-10

Cullinan Therapeutics, Inc. (CGEM) 8-K dated 2026-11-10 — accession 0001193125-26-454408.

Cullinan Therapeutics, Inc. (CGEM) is a biotechnology company listed on US.

CGEM: Cullinan Therapeutics Provides Corporate Update and Reports Third Quart…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported CGEM revenue for 2022-12-31 was $0. Net income was $111.2M. CGEM currently screens at market cap $830.3M.

Not investment advice. The CGEM SEC hub lists recent forms. The stock page is the research view.